Medicinal cannabis products that meet the minimum quality standard

12 April 2021: A new medicinal cannabis products has been verified as meeting the minimum quality standards – Read more.

Generally, medicinal cannabis products are only available, on prescription, if they have:

  • been assessed by the Medicinal Cannabis Agency as meeting the minimum quality standard under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, or
  • obtained consent for distribution under the Medicines Act 1981 (approved and provisionally approved medicines)

Any doctor can prescribe a product listed here. A specialist recommendation and Ministerial approval are not required. For more information on a particular product, please contact the listed product supplier or manufacturer.

Transitional period

The Misuse of Drugs (Medicinal Cannabis) Regulations 2019 included transitional provisions to give manufacturers and importers until 1 October 2020 to put together the information required for the product assessments and to ensure that patients currently accessing these products were able to continue doing so while products were being assessed.

An extension to the transitional period has been granted by the Misuse of Drugs (Medicinal Cannabis) Amendment Regulations 2020 which enables medicinal cannabis products to continue to be supplied without a product assessment until 30 September 2021.

Patients who were prescribed CBD products or medicinal cannabis products that have not been verified against the quality standard may continue to access these products on prescription until 30 September 2021.

Medicinal cannabis products that meet the minimum quality standard under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019

Products that are listed as having been verified as meeting the minimum quality standards are unapproved medicines – there has been no assessment of their safety or efficacy. Being listed here does not guarantee that these products are currently available in New Zealand.

Date Verified Product Dose Form Active Ingredient Pack Sizes Administration Licence Holder
12 April 2021 Tilray FS Oral Solution THC 25 Solution, Oral Total THC (THC+THCA) 26.6 mg / g (25 mg/ mL)

Total CBD (CBD+CBDA) < 0.5 mg/g
40 mL Oral, 1 mL dropper with volume markings CDC Pharmaceuticals Ltd
19 March 2021 Tilray FS Oral Solution THC 10: CBD 10 Solution, Oral Total THC (THC+THCA) 10.6 mg/g

Total CBD  (CBD+CBDA) 10.6 mg/g
25 mL
40 mL
Oral, 1 mL dropper with volume markings CDC Pharmaceuticals Ltd
5 March 2021 Tilray P Oral Solution CBD 100 Solution, Oral Total CBD (CBD+CBDA) 106.4 mg/g (100 mg/mL)

Total THC (THC+THCA) ˂0.1 mg/g
25 mL
40 mL
Oral, 1 mL dropper with volume markings CDC Pharmaceuticals Ltd
5 March 2021 Tilray P Oral Solution CBD 25 Solution, Oral Total CBD (CBD+CBDA) 26.6 mg/g (25 mg/mL)

Total THC (THC+THCA) ˂0.1 mg/g
40 mL Oral, 1 mL dropper with volume markings CDC Pharmaceuticals Ltd

Products with consent for distribution (approved and provisionally approved) under the Medicines Act 1981

Approved and provisionally approved medicines have been assessed by Medsafe and have demonstrated that they meet New Zealand and internationally recognised standards for quality, safety and efficacy. Approved and provisionally approved medicines are not required to be assessed against the minimum quality standard.

Sativex Oral spray
Active ingredient(s) Cannabidiol 25 mg/mL equivalent to Cannabis sativa extract 35 mg–42 mg
Tetrahydrocannabinol 27 mg/mL equivalent to Cannabis sativa extract 38 mg–44 mg
Dose form Oromucosal spray
Sponsor Emerge Health New Zealand Limited
58 Richard Pearse Drive
Airport Oaks, Mangere 2022
Prescribing information Sativex data sheet
Information for consumers Sativex consumer medicine information
Back to top